Business
Premier Biomedical’s CEO, William A. Hartman, Returns to Uptick Network “Stock Day” for an Update on Latest Company Developments
Premier Biomedical’s CEO, William A. Hartman, Returns to Uptick Network “Stock Day” for an Update on Latest Company Developments.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n\n Dallas, TX, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Uptick Newswire announces the return of Mr. William A. Hartman, President & CEO of Premier Biomedical Inc. (OTCQB: BIEI, the “Company”) on the Uptick Network “Stock Day\" Podcast. Mr. Hartman overviewed the Company’s Anti-Cancer R&D program and discussed his intent to find a licensee for the technology or investment partner to complete the development of this very promising anti-cancer antibody drug.\n Mr. Hartman outlined the unique attributes of Premier Biomedical’s topical pain relief products. In addition to the company’s website at www.painreliefmeds.com, the company has also begun selling its products on Amazon.  Mr. Hartman emphasized that the company launched its topical pain relief products with a single product in the first quarter of 2017, a 96-hour skin patch, and has continued to develop and launch additional new products.  By year end, the company will have a total of five topical pain relief products available. Continuing the interview, Mr. Hartman elaborated on Premier Biomedical’s plan to penetrate the professional and collegiate sports medicine arena by adding Carl Eller, President of the NFL retired Players Association, as Marketing and Planning Vice-President. Mr. Eller’s access to retired and active NFL and NCAA players will help the Company penetrate these markets with their expanding array of topical pain relief products. Finally, Mr. Hartman recapped the Company’s plan to expand to large, nation-wide pharmacies, senior living communities, sports activities and off-shore distribution.The topical pain relief products market is estimated to exceed $5 billion within the next five to seven years. Mr. Hartman continued, “The Company is in the process of developing new products that will ensure our competitive edge in the market. It is projected that 71,000 people in the United States will die from opioid related drug overdoses in 2017. We believe that our all-natural topical pain relief products are a viable alternative to dangerous opioid pain killers.  We have attempted to draw attention to our opioid-alternative pain relief products by contacting National and State government agencies engaged in fighting this opioid epidemic. \"Relative to our stock price, our plan for th...